# NCT06769126 (NCT06769126)

> Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06769126
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: SWOG Cancer Research Network
- Conditions: Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype; Lung Small Cell Carcinoma, N Subtype; Lung Small Cell Carcinoma, P Subtype
- Interventions: Biospecimen Collection; Ceralasertib; Computed Tomography; Durvalumab; Etoposide; Magnetic Resonance Imaging; Monalizumab; Platinum Compound; Positron Emission Tomography; Saruparib; Thoracic Radiation Therapy
- Enrollment: 900
- Primary outcome: Screen success rate (Screening)
- Primary outcome: Progression-free survival (PFS) (Cohort A)
- Primary outcome: PFS (Cohort B)
- Primary outcome: PFS (Cohort C)

## Commentary we found

- YouTube: 7
- X threads: 5
- Podcasts: 3
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct06769126

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06769126", "email": "<work email>"}; the inbox owner confirms by the emailed link.